Hello world. There comes a time when that voice inside your head becomes a constant shout ~ "GET OFF YOUR #&% duff and DO SOMETHING - make this world a better place!" So here I go!
I advocate for accessible, affordable & effective HIV treatment & you can too. Empower yourself! Stay informed!
Hello again ~
It’s been a while since my last post. Last week I was at the 2007 14th Conference on Retroviruses and Opportunistic Infections in Los Angeles, CA.
This conference is a science-focused meeting of the world's leading researchers who work to understand, prevent, and treat HIV/AIDS and its complications. In short, CROI is the place where people report on anything big happening in the HIV/AIDS science world. CROI is a huge mental workout because it is geared for scientists, not the average person like you or me. Thus, nothing is easy to understand. They speak in science like, “The influence of single nucleotide polymorphisms (SNP) of the fractalkine (CX3CL1) gene, the natural ligand of the CX3CR1 HIV-1 coreceptor, and of the CCR2 chemokine receptor and CCL2 on the natural history of HIV-1 infection are not known of inconsistent, respectively.” Now don’t get me wrong, I was a science geek in school, but imagine having to take 7 hours of science for four days straight. It was a brain fry to say the least.
Keeping on top of the science, the following are some links to some of what was reported from the conference (compiled by Jules Levin of NATAP):
Metabolic Outcomes of ACTG 5142: A Prospective, randomized Phase III Trial of NRTI, PI, and NNRTI-sparing Regimens for Initial Treatment of HIV (03/05/07)
Significant Sparing of Peripheral Lipoatrophy by HIV Treatment with LPV/r (Kaletra) + AZT/3TC Induction Followed by LPV/r Monotherapy Compared with EFV +AZT/3TC (03/05/07)
Body Composition Changes in ARV-Naive Subjects Treated With Atazanavir or Atazanavir/Ritonavir-Based Once-Daily HAART: 48-Week CT and DEXA Data (03/05/07)
Entecavir HBV Therapy: does it have HIV activity? (03/05/07)
Insulin Resistance Predicts Rapid Response in People With HCV and HIV - written by Mark Mascolini (03/05/07)
CD4 Count Predicts Fatal Non-AIDS Cancers: Traditional Malignancies May also be AIDS-Related - Reported by David Alain Wohl (03/05/07)
Higher CD4 Count Prevents End-Organ Diseases (03/05/07)
HIV-Related Kidney Disease, ART Effects - Written by Christina Wyatt (03/05/07)
Acute HIV infection: Transmitted Resistance in Newly Infected Patients - written by Charles Hicks, M.D. (03/05/07)
Results of BENCHMRK-1, a Phase III Study Evaluating the Efficacy and Safety of Raltegravir (MK-0518), a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus (03/05/07)
Motivate 1 Study: Efficacy and Safety of Maraviroc plus Optimized Background Therapy In Viremic, ART-Experienced Patients Infected With CCR5-Tropic HIV-1: 24-Week Results of Phase 2b/3 Studies (03/05/07)
Increase in AIDS Cases (03/02/07)
Disparities in Life Expectancy Due to Suboptimal HIV Care in the US: Impact of Gender, Ethnicity and Race: (03/02/07)
Osteopenia in HIV: risk factors for screeing - written by Carl J. Fichtenbaum, M.D. (03/02/07)
Results from Two Phase III Studies on ISENTRESS (raltegravir, MK-0518), Merck's Oral Investigational Integrase Inhibitor Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI) - Press Release (03/02/07)
Pfizer's Maraviroc, Novel Medicine For HIV, Significantly Reduces Viral Load, in Combination Therapy Across Range of Treatment-Experienced Patients - Press Release (03/02/07)
Metabolic and Cardiovacular Complications in HIV - written by Carl J. Fichtenbaum, M.D. (03/01/07)
Maraviroc Combined Analysis & MOTIVATE 2 (Europe, Australia, USA): 24 week Results (03/01/07)
Gilead Integrase Inhibitor Outdoes New PIs in Salvage Therapy - written by Mark Mascolini (03/01/07)
TMC278 Matches Efavirenz in Treatment-Naive People - written by Mark Mascolini(03/01/07)
Three new drugs promise options for HIV patients (03/01/07)
Lipodystrophy/Metabolic Complications of ART in South Africa (03/01/07)
Adverse Events/Complications of ART in Africa (03/01/07)
48-week primary analysis of trial TMC278- C204: TMC278 demonstrates potent and sustained efficacy in ARV-naive patients (03/01/07)
The HIV Integrase Inhibitor GS-9137 Has Potent Antiretroviral Activity in Treatment-Experienced Patients (03/01/07)
New HIV Drugs; Intl Drug Resistance (02/28/07)
Do Trace Levels of Resistance Affect Virologic Response? - written by Mark Mascolini (02/28/07)
Pfizer CCR5 Maraviroc 24 Weeks In Treatment-Experienced (02/28/07)
Lower CD4 Counts Boost Risk of "Non-AIDS" Cancers - written by Mark Mascolini (02/28/07)
People With HIV Infection Eat Too Much Saturated Fat - written by Mark Mascolini (02/28/07)
Integrase Inhibitor Adds More Punch to Salvage Regimens - written by Mark Mascolini (02/28/07)
Life Expectancy With HIV Still Low in High-Income Countries - written by Mark Mascolini (02/28/07)
CCR5 Blocker Looks Strong in Two International Salvage Trials - written by Mark Mascolini (02/28/07)
Nations Defend HIV Drugs With Tests for Hardy Strains (02/26/07)
Drug-resistant TB that kills HIV patients is spreading (02/26/07)
Alendronate with Calcium and Vitamin D Supplementation Is Superior to Calcium and Vitamin D Alone in the Management of Decreased Bone Mineral Density in HIV-infected patients: Results of ACTG 5163 (02/26/07)
Metabolic Outcomes of ACTG 5142: A Prospective, Randomized phase III trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial treatment of HIV-1 (02/26/07)
Effects of TH9507, a Growth Hormone Releasing Factor Analog, on HIV-associated Abdominal Fat Accumulation: A Multicenter, Double-blind Placebo-controlled Trial with 412 Randomized Patients (02/26/07)
Starting Antiretrovirals Later May Hurt Cognitive Function - written by Mark Mascolini (02/26/07)
Ezetimibe Reduces LDL-C for HIV+ on HAART (02/26/07)
How Antiretroviral Breaks May Raise Heart Disease Risk - written by Mark Mascolini (02/26/07)
CD4 Counts Predict Non-AIDS Disease Risk in FIRST Trial - written by Mark Mascolini (02/26/07)
Therapies for Improved Lipids, Belly Fat, and Limb Fat (02/26/07)
Also….. check out my interview with Steve Felstead, Pfizer VP, about Maraviroc the first-in-class CCR5 inhibitor. http://video.google.com/videoplay?docid=-2101100643582810605&pr=goog-sl&hl=en.
Hello again ~
If you haven’t done so already, please read the January 3 article “Inside Abbott's tactics to protect AIDS drug” published in the Wall Street Journal and available online at http://post-gazette.com/pg/07003/750966-28.stm … Thank you, John Carreyrou, for telling the Abbott-Norvir story to the world. Also see related story Poz.com story "WSJ Uncovers Abbott's Norvir-Busting Marketing Strategies" http://www.poz.com/articles/761_11084.shtml.
Yes, in the HIV/AIDS activists’ realm, we refer to Abbott as “the greedy, dirty bastards.” My center (The Center for AIDS Information & Advocacy) vehemently decried their evils and helped lead the boycott against Abbott alongside many other prominent activists in the AIDS Treatment Activists Coalition (ATAC) http://www.emediawire.com/releases/2004/7/emw142638.htm. Our center dropped its boycott of Abbott in December 2005 because of the postitive strides Abbott has made in the Houston community.
Carreyrou wrote, “Over time, the outcry faded . . ” I am here to bear witness that in the HIV/AIDS activists’ realm, the Novir pricing issue has faded as much as Japan’s attack on Pearl Harbor has ~ meaning, of course, it hasn’t and never will!
In fact, we advocates are still at each other’s throats over the issue. Basically, there are two hunkered-down camps: the “don’t ever talk to those dirty bastards” group verses the “they’ve made strides, so let’s start the mend” group. Either way, the bigger issue remains that the Norvir price increase, and subsequent monopoly on the “boosting” market, proved(s) how low a company would stoop to make money.
Here’s our new Texas war cry: REMEMBER THE ALAMO; REMEMBER NORVIR!!!
Those greedy bastards!
I loved, loved, loved Poz Magazine's 35 Ones-to-Watch list (http://www.poz.com/articles/1891_10868.shtml).
Yes, grassroots activists Julie David’s and Gregg Gonsalves have taken HIV advocacy to a higher realm ~ heck, they’ve rewritten the how-to manual. We follow in their dust.
I’m also pleased to see “Southern spitfire” Joyce Turner-Keller and Phill Wilson included. Charisma is thy name. I just can’t wait to hear what they do and say next.
I would have liked to seen more Southern grassroots spitfires such as: Tom Gegeny, former editor of RITA! (Research Initiative Treatment ACTION!); Judith Dillard, activist and peer educator; and Karen Bates, co-chair of South Carolina Campaign to End AIDS.
Lastly, next year’s list should most definitely include the Ms. Lynda Dee, director of AIDS Action Baltimore. She is a mover of mountains and shaker of people. When she talks, people listen ~ they have to because her unabashed opinions will not be stifled ~ oh, hell no!
I totally get that any “HIV is a gay disease” campaign seeks to empower the gay community and to call people into action. There is nothing wrong with taking ownership of issues in our communities to spur action. However, I fear that directing this particular message to the gay community sends the dangerous message that if you are not in and of that community, you are in the clear. We have made so many strides since the 1980s in getting the word out that HIV/AIDS is a huge issue that goes beyond the borders of the gay community. It would be a shame to see any step backwards. While true, HIV/AIDS is a gay disease, it is also a black disease, a Hispanic disease, a woman/man disease, and so on. Bottom line, it’s an equal-opportunity human disease. So let’s not leave anyone out of that message.
Hello again ~ Tomorrow, December 1, is Worlds AIDS Day. If you’ve been living under a rock since 1988, you many not know this.
Now you would think that I would gung-ho about it and want to write inspiring words as to why we should all join hands and come together during this day of remembrance. Nope ~ not this chic, not on this blog. You see, I despise that this day has become a “We are the World” kind of moment where people light candles and sing songs in remembrance of a relative or a friend who died of AIDS.
Don’t get me wrong ~ I support people who do this and I certainly support rich celebrities who publicize AIDS, especially AIDS in Sub Saharan Africa, one of the hardest hit areas. But what I am saying is that we should turn World AIDS Day into World AIDS ACTION Day. Really! Wouldn’t it be great if in addition to attending a church service, lighting a candle, walking in a vigil if people time out to talk to call or write his or her state and national legislators to demand more funding for AIDS research, testing and treatment. Wouldn’t it be great if all of our leaders got inundated with calls and emails? How great would that be?
How much clearer can I (we activists) make it! Every year, the number of people being infected INCREASE…get bigger…become larger…I don’t know how many more ways to say it!!! Women, especially women of color, are increasingly being infected. So for me World AIDS Day is a reminder of these pitiful facts and personally I am saddened and embarrassed ~ aren’t you?
People ask me what they can do, well, here is a list:
That’s it. 4 things. Yes, we can shout it to the rooftops ~ and have been. But while these “how not to get HIV” tips do work, no one can’t dictate to others how to live their lives. No one can be the “condom” or the “no sex, no drugs” police. No on can point a gun to people and tell people to only do things that are good (but don’t feel good) for them like wearing a helmet when riding a motorcycle, putting on a seat belt, eating right and so on. It doesn’t work like that. People are human. We make our own choices based upon many, many factors and variables. And I’ll admit. I’ve done risky things, and will unfortunately continue to do risky things. So then the question becomes: how far I am willing to go to risk my health or wellness? Bottom line, like it or not, to solve our issues, we need to take personal responsibility. And we need to be accountable for our own actions…PERIOD. I am not saying that is good or bad, it’s just a fact of life.
So here is the deal. If you want to see change, look at the person in the mirror and start there. If you want more change, start the person next door and work from there. If you truly want more change, get a blog, write a letter to an editor, attend a meeting…just do something, anything. Of course I can't point a gun to your head, can I?
Add An HIV/AIDS treatment advocate's blog to your personalized My Yahoo! page: